Research Article| Volume 155, ISSUE 3, P406-412, December 2019

Download started.


Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial

Published:October 30, 2019DOI:


      • Bevacizumab combined with chemotherapy does not increase PFS in comparison to chemotherapy in recurrent endometrial cancer.
      • Cardiovascular events were more frequent in the bevacizumab arm.
      • Secondary endpoint suggests activity of bevacizumab in endometrial cancer which merits further exploration.



      Increased Vascular Endothelial Growth Factor Receptor (VEGF) expression in endometrial cancer (EC) is associated with a poor prognosis. Preliminary clinical data reported Bevacizumab effectiveness in EC both as single agent and in combination with chemotherapy.


      In a phase II trial, patients with advanced (FIGO stage III-IV) or recurrent EC were randomized to receive Carboplatin-Paclitaxel standard dose for 6–8 cycles vs Carboplatin-Paclitaxel and Bevacizumab 15 mg/kg in combination with chemotherapy and maintenance until disease progression or unacceptable toxicity. The primary endpoint was progression free survival (PFS).


      108 patients were randomized; PFS (10.5 vs 13.7 months, HR 0.84 p = 0.43), overall response rate (ORR 53.1% vs 74.4%) and overall survival (OS) (29.7 vs 40.0 months, HR 0.71 p = 0.24) resulted in a non-significant increase in Bevacizumab treated patients. The PFS increase became significant when an exploratory analysis with the Breslow test was used. Moreover, patients treated with Bevacizumab experienced a significant increase in 6-month disease control rate (70.4% vs 90.7%). Cardiovascular events were more frequent in the experimental arm (“de novo” grade ≥2 hypertension 21% vs 0% and grade ≥2 thromboembolic events 11% vs 2% in the Bevacizumab vs standard treatment arm, respectively).


      Bevacizumab combined with chemotherapy in the treatment of advanced/recurrent EC failed to demonstrate a significant increase in PFS in the MITO END-2 trial. Nevertheless, these preliminary data suggests some effectiveness of the antiangiogenic agent which merits further exploration in a larger population with a better molecular characterization.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sorosky J.I.
        Endometrial cancer.
        Obstet. Gynecol. 2012 Aug; 120: 383-397
        • Miller D.F.V.
        • Fleming G.
        • Mannel R.
        • Cohn D.
        • Matsumoto T.
        • Tewari K.
        • et al.
        Randomized phase III non inferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a gynecologic oncology group study. [SGO abstract LBA-1].
        Gynecol. Oncol. 2012; 125: 771-773
        • Yokoyama Y.
        • Charnock-Jones D.S.
        • Licence D.
        • Yanaihara A.
        • Hastings J.M.
        • Holland C.M.
        • et al.
        Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
        Clin Cancer Res Apr. 2003; 9: 1361-1369
        • Sanseverino F.
        • Santopietro R.
        • Torricelli M.
        • D’Andrilli G.
        • Russo G.
        • Cevenini G.
        • et al.
        pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade.
        Cancer Biol Ther Jan. 2006; 5: 84-88
        • Kamat A.A.
        • Merritt W.M.
        • Coffey D.
        • Lin Y.G.
        • Patel P.R.
        • Broaddus R.
        • et al.
        Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
        Clin. Cancer Res. 2007; 13 (Dec 15): 7487-7495
        • McMeekin D.S.
        • Sill M.W.
        • Benbrook D.
        • Darcy K.M.
        • Stearns-Kurosawa D.J.
        • Eaton L.
        • Gynecologic Oncology Group
        • et al.
        A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
        Gynecol Oncol May. 2007; 105: 508-516
        • Hirai M.
        • Nakagawara A.
        • Oosaki T.
        • Hayashi Y.
        • Hirono M.
        • Yoshihara T.
        Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma.
        Gynecol Oncol Feb. 2001; 80: 181-188
        • Davies S.
        • Dai D.
        • Pickett G.
        • Thiel K.W.
        • Korovkina V.P.
        • Leslie K.K.
        Effects of bevacizumab in mouse model of endometrial cancer: defining the molecular basis for resistance.
        Oncol Rep Mar. 2011; 25: 855-862
        • Cerezo L.
        • Cárdenes H.
        • Michael H.
        Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications.
        Clin Transl Oncol Apr. 2006; 8: 231-241
        • Aghajanian C.
        • Sill M.W.
        • Darcy K.M.
        • Greer B.
        • McMeekin D.S.
        • Rose P.G.
        • et al.
        Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
        J Clin Oncol Jun 1. 2011; 29: 2259-2265
        • Simpkins F.
        • Drake R.
        • Escobar P.F.
        • Nutter B.
        • Rasool N.
        • Rose P.G.
        A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA).
        Gynecol Oncol Feb. 2015; 136: 240-245
        • Breslow N.
        Statistical methods for censored survival data.
        Environ. Health Perspect. 1979 Oct; 32 (PubMed PMID: 396152; PubMed Central PMCID: PMC1637936): 181-192
      1. Lorusso D, Ferrandina G, Colombo N, S. Pignata, A. Pietragalla, C. Sonetto, et al., Randomized phase II trial of carboplatin-paclitaxel (CP) compared to carboplatin-paclitaxel-bevacizumab (CP-B) in advanced (stage III-IV) or recurrent endometrial cancer: the MITO END-2 trial. J. Clin. Oncol. 33, 2015 (suppl; abstr 5502).

        • Aghajanian C.
        • Filiaci V.
        • Dizon D.S.
        • Carlson J.W.
        • Powell M.A.
        • Secord A.A.
        • et al.
        A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
        Gynecol. Oncol. 2018 Aug; 150 (Epub 2018 May 24): 274-281
        • Kandoth C.
        • Schultz N.
        • Cherniack A.D.
        • Akbani R.
        • Liu Y.
        • Shen H.
        • et al.
        Cancer genome Atlas research network, integrated genomic characterization of endometrial carcinoma.
        Nature. 2013; 497 (May 2): 67-73
        • Mallen A.R.
        • Filiaci V.L.
        • Levine D.A.
        • Thield K.
        • Aghajaniane C.A.
        • Mengf X.
        • et al.
        Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers.
        Oral presentation at: Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, New Orleans, LA. 2018; (March 24-27)
        • Lambrechts D.
        • Lenz H.J.
        • de Haas S.
        • Carmeliet P.
        • Scherer S.J.
        Markers of response for the antiangiogenic agent bevacizumab.
        J. Clin. Oncol. 2013; 31 (Mar 20): 1219-1230
        • FDA
        KEYTRUDA® (pembrolizumab) highlights of prescribing information.